New drug combo targets tough breast cancer in Real-World study
NCT ID NCT07543250
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a drug called inavolisib works in real-world settings for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will take inavolisib along with hormone therapy, sometimes with another drug. Researchers will track how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inavolisib (a targeted cancer drug) combined with endocrine therapy, with or without a CDK4/6 inhibitor
What this could lead to
If successful, this could provide a new treatment option for people with a specific type of advanced breast cancer, potentially slowing disease progression.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and may not show clear benefits or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••